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Possible failure of novel direct-acting oral
anticoagulants in management of
pulmonary embolism: a case report
James Rankin1*, Menachem Nagar1, Jonathan Crosby1, Nojan Toomari1, Richard Pietras2 and Uri M. Ben-Zur1,2
Abstract
Background: The relative effectiveness of vitamin K antagonists compared with novel oral anticoagulants in
treating pulmonary embolism remains unclear. Recent trials comparing the efficacy of vitamin K antagonists with
factor Xa inhibitors for the treatment of pulmonary emboli have been non-inferiority studies based primarily on risk
reduction (such as bleeding events), rather than resolution of specific diseases such as pulmonary embolism.
Consequently, there is a lack of evidence indicating which of these agents are more effective. Here, we present a
case where pulmonary emboli were treated with novel oral anticoagulants followed by warfarin to discuss the
potential limitations in the use of novel oral anticoagulants as prevention or treatment of thromboembolism and
the continued role for warfarin in this setting.
Case presentation: A 34-year-old African American woman presented to our clinic with shortness of breath and
pleuritic chest pain several months post-surgery. She was identified as having multiple bilateral pulmonary
embolisms and was treated with several novel oral anticoagulants, which failed to resolve the clots. Complete
resolution was achieved upon switching to warfarin.
Conclusions: The patient described in this report failed to respond to novel oral anticoagulant therapy, but her
emboli resolved when she was treated with warfarin. This study challenges the notion that factor Xa inhibitors are
better alternatives to vitamin K anticoagulants in the treatment of pulmonary emboli based on their safety profile
and ease of use alone. As a result, further post-marketing investigations into the efficacy of these agents in the
management of pulmonary emboli may be warranted.
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Background
Venous thromboembolism (VTE) is a condition that
comprises deep vein thrombosis (DVT) with or without
the presence of systemically circulating emboli; it in-
cludes conditions such as pulmonary embolism (PE).
Prevention and treatment of VTE are imperative due to
the significant morbidity and risk of mortality involved.
Currently, agents available to treat this condition are
limited and, among these, the mainstay of both preven-
tion and treatment for over 60 years has been warfarin
(Coumadin®; also Jantoven® and Marevan®), which is an
oral vitamin K antagonist (VKA). However, warfarin
treatment is inconvenient due to its increased risk of ad-
verse events (that is, bleeding), which makes it an un-
desirable option [1, 2].
In response, new agents were developed to improve
patients’ quality of life and to decrease the risk of bleed-
ing in those requiring long-term anticoagulation. One
class of these newer agents, the novel oral anticoagulants
(NOACs) including direct factor Xa inhibitors (FXaI)
and direct thrombin inhibitors, is quickly becoming the
standard of care as first-line agents due to clear advan-
tages with regard to monitoring and risks of adverse
events. However, at this point, there is limited long-term
data to determine all factors for their use in special cir-
cumstances. Here we present a case of a medication-
compliant patient who experienced recurrent pulmonary
emboli, yet failed to resolve these emboli on initial
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treatment with multiple NOACs, reaching complete
resolution of emboli only after being switched to war-
farin treatment.
Case presentation
Our patient is a 34-year-old obese (body mass index,
BMI, 31.09 kg/m2) African American woman with a his-
tory of an undefined congenital septal defect, the status
of which is post-surgical repair, and congenital clubfoot,
who also underwent calcaneal tendon repair in May of
2015. Afterward, she remained sedentary for several
weeks and then began to report progressively worsening
non-exertional dyspnea that was associated with sharp
intermittent chest pain. On 31 May 2015, she presented
to her local emergency department for dyspnea on in-
spiration and “stabbing” pleuritic chest pain at bilateral
lung bases. A computed tomography (CT) angiogram of
her chest was performed, demonstrating multiple bilat-
eral PEs (Fig. 1). She was then admitted to a hospital
and started on rivaroxaban (Xarelto®, Janssen) dosed at
15 mg administered orally once a day. In September
2015, despite compliance with her rivaroxaban therapy
for several months, a ventilation-perfusion (V/Q) scan
demonstrated multiple bilateral pulmonary emboli.
Rivaroxaban was discontinued and she was switched to
dabigatran (Pradaxa®, Boehringer Ingelheim) 150 mg ad-
ministered orally twice daily. Within a few days, she de-
veloped acute severe hip joint pain. She was then
switched to apixaban (Eliquis®, Bristol-Myers Squibb) at
5 mg administered orally twice daily. On a follow-up
V/Q scan in January 2016, she was found to have
persistent PEs; she was then referred to our clinic.
Based on prior studies, apixaban was discontinued and
warfarin therapy was initiated at 10 mg administered or-
ally one a day with a goal of international normalized
ratio (INR) 2.0–3.0, requiring weekly INR checks with
appropriate dosing adjustments. She reported gradual
progressive improvement and in March 2016 a CT angi-
ography of her chest was performed with no evidence of
pulmonary arterial thrombi or emboli (Fig. 2).
Conclusions
For over 60 years, warfarin has been the standard out-
patient management option for VTE. It has proven
efficacy for this indication, significantly decreasing
thromboembolic events while maintaining an acceptable
level of adverse events, primarily bleeding episodes
[1, 3]. This has been confirmed by numerous prospective
studies and in post-marketing clinical use, including trials
conducted to compare the efficacy of conventional doses
of warfarin with low doses for providing anticoagulation.
Conventional doses of warfarin (INR 2.0–3.0) were shown
to provide superior treatment for VTE when compared
with low-dose therapy (INR 1.5–1.9), notably with no sig-
nificantly increased risk for "clinically important" bleeding
[1]. However, warfarin use is not straightforward and
requires: (a) bridging therapy (the use of parenteral anticoag-
ulants until appropriate levels are attained), (b) frequent
Fig. 1 Computed tomography angiography of the chest with right-sided arterial emboli. Coronal section of this patient’s computed tomography
angiography demonstrates a filling defect within the pulmonary vasculature, most likely representing emboli. At the time of this study, the patient
was being treated with a novel oral anticoagulant (rivaroxaban)
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monitoring of individualized dosing to maintain INR levels
within a narrow therapeutic window (in most instances,
an INR goal between 2 and 3), and an (c) awareness of the
significant risk of adverse bleeding events requiring
potentially inconvenient lifestyle modifications [2].
Bleeding events associated with warfarin use range in
severity from minor to fatal. One report indicated that
warfarin elicited twice as many major bleeding episodes
as placebo, while another found the incidence of major
bleeding episodes in patients with a target INR greater
than 3.0 to be twice as high as in those with a target
between 2.0 and 3.0 [4, 5].
Alternatively, novel direct-acting oral anticoagulants
aim to provide a safer, more tolerable, treatment option as
compared to warfarin to prevent and treat DVT, PE, and
atrial fibrillation (Afib) [3, 6]. Benefits of novel direct-
acting oral anticoagulants include: (a) no need to monitor
INR levels, and (b) potentially decreased drug interactions
and adverse events (such as bleeding episodes). One family
of novel direct-acting oral anticoagulants, the direct FXaIs,
such as rivaroxaban (Xarelto®) and apixaban (Eliquis®), were
only made available in the USA as recently as 2010 [7]. This
family of drugs all share a similar mechanism of action,
inhibiting the cleavage of prothrombin into thrombin
during the final step of the common coagulation cascade.
Several trials have compared FXaIs with warfarin in
treating VTE. The EINSTEIN–PE trial showed rivaroxaban
to be non-inferior to warfarin regarding PE treatment and
demonstrated no difference in overall bleeding events [8].
Similarly, the AMPLIFY and Hokusai-VTE trials showed
non-inferiority of apixaban and edoxaban, respectively,
when compared with warfarin in the treatment of VTE,
with a significant reduction in bleeding events [9, 10].
However, it is important to note that the trials re-
ported to date have largely been non-inferiority studies,
not equivalency or superiority studies. Data reported in
the EINSTEIN–PE trial showed a downward trend in
VTE episodes among those treated with warfarin versus
rivaroxaban, but displayed a reduced number of bleeding
episodes in the rivaroxaban group as compared with the
warfarin group [8]. Most of these studies focused on
treatment of VTE as a single category (DVT with or
without non-fatal or fatal PEs), rather than reporting on
the analysis of separate subsets (DVT, non-fatal PEs,
fatal PEs, and so forth) contained within this larger
group. Only one study, the EINSTEIN–PE trial, provided
insight into the treatment of PE in isolation, revealing a
trend toward superiority in warfarin-treated patients
over FXaI in both non-fatal and fatal PE categories [8].
As a consequence of data available from these several
recent trials, clinical guidelines, such as those of the
“CHEST Guideline and Expert Panel Report”, now rec-
ommend use of newer agents, such as dabigatran, rivar-
oxaban, apixaban and edoxaban, rather than VKAs to
manage patients with lower extremity VTE [11].
It is clear that non-inferiority studies are useful to de-
termine the general safety profile of a novel therapeutic
agent while retaining the efficacy of an accepted thera-
peutic standard. However, the lack of equivalency or su-
periority data and the absence of findings in established
subsets of affected patients impede a clinician’s ability to
critically evaluate what therapeutic agent may be best in
Fig. 2 Computed tomography angiography of the chest without any evidence of emboli. A follow-up computed tomography after discontinuation of
novel oral anticoagulant therapy and initiation of closely monitored conventional warfarin anticoagulation (international normalized ratio
2.0–3.0). A coronal section of this study at the same level as Fig. 1 reveals vessels filled with intravenous contrast indicating patency
without the presence of emboli
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treating specific conditions. Trials for new medica-
tions allow for the discovery and validation of agents,
while decreasing potential risks, but these data should
be regarded as tentative until more definitive studies
have been performed in large populations, determin-
ing where the most benefit can be derived with the
least possible risk.
It is accepted that common risk factors for clot forma-
tion include tobacco use, a history of coagulopathy, and/
or the use of oral contraception. The patient in this
report was counseled on these risk factors and denied ei-
ther a history of tobacco use or clotting dysfunction; how-
ever, she was determined to be on levonorgestrel-releasing
intrauterine system (Skyla®, Bayer). Although intrauterine
devices are impregnated with hormonal contraceptive
agents and carry a risk of thrombosis, Skyla was not re-
ported to induce any cases during clinical trials, only as a
part of post-marketing studies, and she developed clots
after long-term use of this device [12].
Without significant retrospective analyses or random-
ized prospective trials with subgroup analyses, it is diffi-
cult to determine whether VKAs or FXaIs are truly
more effective in the treatment of PE. This assessment is
especially difficult when taking into account the diagnos-
tic modalities and treatments provided for this patient
prior to arrival in our clinic. Although she was initially
followed with serial V/Q scans to determine the success
of her treatments, the EINSTEIN–PE investigators and
our clinic elected to use CT angiography in view of its
substantially increased resolution [8]. In addition, prior
to arrival in our clinic, she was treated with rivaroxaban
at 15 mg administered orally once a day, as opposed to
the generally recommended initial dose of 20 mg admin-
istered orally, followed by 15 mg administered orally
twice a day [13]. In the case of rivaroxaban, in particular,
these are important variables, because it is difficult to as-
certain the effectiveness of a treatment if the standard of
care is not being followed. However, the patient in this
report was later managed with dabigatran and apixaban
in accord with the recommended guidelines [14, 15].
We suggest that further investigations are needed to
establish if novel direct-acting oral anticoagulants are
equal to warfarin in the prevention and treatment of
VTEs, including DVT and PE. Further, we suggest that
practitioners carefully weigh the risks and benefits when
selecting these medications. We note that Rudd et al.
have reported independently on possible rivaroxaban
failure in patients treated during the postpartum period,
possibly due to pharmacokinetic alterations seen in the
postpartum period that can contribute to decreased drug
exposure and reduced anticoagulant efficacy [16]. In fact,
rivaroxaban is well known to be metabolized by the
cytochrome P450 isoenzyme CYP 3A4 and binds to P-
glycoprotein; hence, leading to risks of pharmacokinetic
interactions that may alter its anticoagulant properties
[17]. In practice, it may be best at this time to choose
between these several available anticoagulant drugs on a
case-by-case basis, taking into account patient prefer-
ences, monitoring constraints, difficulty controlling the
INR, the risk of bleeding and interactions, and the cost
of treatment [18].
Abbreviations
Afib: Atrial fibrillation; BMI: Body mass index; CT: Computed tomography;
DVT: Deep vein thrombosis; FXaI: Factor Xa inhibitor; INR: International
normalized ratio; NOAC: Novel oral anticoagulant; PE: Pulmonary embolism;
VKA: Vitamin K antagonist; V/Q: Ventilation-perfusion; VTE: Venous
thromboembolism
Acknowledgements
This work was done with the support of Uri Ben-Zur, MD and the
Cardiovascular Institute of Los Angeles, both instrumental in helping to
make this work possible.
Funding
All funding for this study was provided by U. Ben-Zur, MD, FACC. No outside
funding was obtained.
Availability of data and materials
Not applicable.
Authors’ contributions
JR acquired the data, prepared the clinical information, and was the main
contributor in drafting the manuscript. MN assisted in drafting the
manuscript and providing revisions. JC assisted in acquiring and preparing
the clinical information and providing revisions. NT, RP, and UB were all
instrumental in drafting the manuscript and providing feedback. UB
provided guidance in this process and designed the use of this case and the
format. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Written informed consent was obtained from the patient for publication of
this case report and any accompanying images. A copy of the written
consent is available for review by the Editor-in-Chief of this journal.
Ethics approval and consent to participate
Not applicable.
Author details
1Division of Cardiology, Providence-Tarzana Medical Center, Tarzana, CA
91356, USA. 2Department of Medicine, UCLA David Geffen School of
Medicine, Los Angeles, CA 90095, USA.
Received: 5 September 2016 Accepted: 7 November 2016
References
1. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA,
MacKinnon B, Weitz JI, Crowther MA, Dolan S, Turpie AG, Geerts W,
Solymoss S, van Nguyen P, Demers C, Kahn SR, Kassis J, Rodger M,
Hambleton J, Gent M, Extended Low-Intensity Anticoagulation for
Thrombo-Embolism Investigators. Comparison of low-intensity warfarin
therapy with conventional-intensity warfarin therapy for long-term
prevention of recurrent venous thromboembolism. N Engl J Med.
2003;349:631–9.
2. Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR,
Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA,
Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ. Long-Term, Low-
Intensity Warfarin Therapy for the Prevention of Recurrent Venous
Thromboembolism. N Engl J Med. 2003;348:1425–34.
Rankin et al. Journal of Medical Case Reports  (2016) 10:346 Page 4 of 5
3. Clayville LR, Anderson KV, Miller SA, St. Onge EL. New Options in
Anticoagulation for the Prevention of Venous Thromboembolism and
Stroke. Pharm Ther. 2011;36:86–99.
4. Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P,
Christiansen AV, Friedman J, Le Maulf F, Peter N, Kearon C, for the RE-COVER
II Trial Investigators. Treatment of Acute Venous Thromboembolism with
Dabigatran or Warfarin and Pooled Analysis. Circulation. 2014;129:764–72.
5. Molteni M, Cimminiello C. Warfarin and atrial fibrillation: from ideal to real
the warfarin affaire. Thromb J. 2014;12:5.
6. Dobesh PP, Fanikos J. New Oral Anticoagulants for the Treatment of Venous
Thromboembolism: Understanding Differences and Similarities. Drugs.
2014;74:2015–32.
7. Cabral KP, Ansell JE. The role of factor Xa inhibitors in venous
thromboembolism treatment. Vasc Health Risk Manag. 2015;11:117–23.
8. The EINSTEIN–PE Investigators. Oral Rivaroxaban for the Treatment of
Symptomatic Pulmonary Embolism. N Engl J Med. 2012;366:1287–97.
9. Hokusai-VTE Investigators, Büller HR, Décousus H, Grosso MA, Mercuri M,
Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A,
Shi M, Verhamme P, Wells P. Edoxaban versus warfarin for the treatment of
symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406–15.
10. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz
U, Pak R, Thompson J, Raskob GE, Weitz JI. AMPLIFY Investigators. Oral
apixaban for the treatment of acute venous thromboembolism. N Engl J
Med. 2013;369:799–808.
11. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman
M, King CS, Morris TA, Sood N, Stevens SM, Vintch JRE, Wells P, Woller SC,
Moores L. Antithrombotic Therapy for VTE Disease: CHEST Guideline and
Expert Panel Report. Chest. 2016;149:315–52.
12. Bayer HealthCare Pharmaceuticals Inc.: SKYLA (levonorgestrel-Releasing
Intrauterine System). Whippany, NJ; 2013. https://dailymed.nlm.nih.gov/
dailymed/drugInfo.cfm?setid=9f44ff35-e052-49cd-a1c2-0bfd87d49309.
13. Janssen: Xarelto (rivaroxaban). Titusville, NJ; 2014. https://dailymed.nlm.nih.
gov/dailymed/drugInfo.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610.
14. Bristol-Myers Squibb: Eliquis (apixaban) Oral Tablets Prescribing Information.
Princeton, NJ; 2014. https://dailymed.nlm.nih.gov/dailymed/drugInfo.
cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b0.
15. Boehringer Ingelheim: Pradaxa (dabigatran Etexilate Mesylate). Ridgefield,
CT; Aug 2014. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=
ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.
16. Rudd KM, Winans ARM, Panneerselvam N. Possible Rivaroxaban Failure
during the Postpartum Period. Pharmacotherapy. 2015;35:e164–168.
17. Nutescu EA, Burnett A, Fanikos J, Spinler S, Wittkowsky A. Pharmacology of
anticoagulants used in the treatment of venous thromboembolism. J
Thromb Thrombolysis. 2016;41:15–31.
18. Rivaroxaban: new drug. After hip or knee replacement surgery: LMWH is
safer. Prescrire Int. 2009;18:151–3.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Rankin et al. Journal of Medical Case Reports  (2016) 10:346 Page 5 of 5
